

Renal Epithelial Neoplasms



Histopathology Reporting Guide		
Family/Last name	Date of birth DD - MM - YYYY	
Given name(s)		
Patient identifiers	Date of request Accession/Laboratory number	
	DD - MM - YYYY	
Elements in black text are CORE. Elements in grey text are NON-CORE. indicates multi-select values indicates single select values		
PRE-OPERATIVE TREATMENT (select all that apply) Tumour embolisation Cryoablation Radio frequency ablation External-beam radiation therapy (EBRT) Neoadjuvant systemic therapy Other, specify	TUMOUR SITE (select all that apply) Upper pole Mid kidney Lower pole Cortex Medulla Other, specify	
	TUMOUR FOCALITY Cannot be assessed	
OPERATIVE PROCEDURE Not specified Radical nephrectomy Total (simple) nephrectomy Partial nephrectomy Other, specify	Unifocal Multifocal Specify number of tumours MAXIMUM TUMOUR DIMENSION (If multiple tumours the maximum dimension of up to the largest five should be recorded)	
	Cannot be assessed	
	Tumour 1 mm Tumour 4 mm	
SPECIMEN LATERALITY	Tumour 2 mm Tumour 5 mm	
Not specifiedLeftRight	Tumour 3 mm	
Other (e.g., horseshoe kidney), specify	(List overleaf or separately with an indication of the nature and origin of all tissue blocks)	
ACCOMPANYING/ATTACHED STRUCTURES (select all that approximately not submitted Adrenal gland Lymph nodes, specify	HISTOLOGICAL TUMOUR TYPE ^a (select all that apply) (Value list based on the World Health Organization Classification of Urinary and Male Genital Tumours (2022)) Clear cell renal cell carcinoma Multilocular cystic renal neoplasm of low malignant potential Papillary renal cell carcinoma	
Other organs, specify TISSUE REMOVED FROM SPECIMEN PRIOR TO SUBMISSION No Yes, specify	Chromophobe cell renal carcinoma Other oncocytic tumours of the kidney Collecting duct carcinoma Clear cell papillary renal cell tumour Mucinous tubular and spindle cell carcinoma Tubulocystic renal cell carcinoma Acquired cystic disease—associated renal cell carcinoma Eosinophilic solid and cystic renal cell carcinoma	
	Renal cell carcinoma, not otherwise specified (NOS)	

HISTOLOGICAL TUMOUR TYPE continued	EXTENT OF INVASION
☐ <i>TFE3</i> -rearranged renal cell carcinomas	Tumour limited to the kidney
TFEB-altered renal cell carcinomas	Tumour in perinephric fat
☐ ELOC (formerly TCEB1)-mutated renal cell carcinoma	Cannot be assessed
Fumarate hydratase-deficient renal cell carcinoma	Not identified
Hereditary leiomyomatosis and renal cell carcinoma	○ Present
(HLRCC) syndrome–associated renal cell carcinoma	Tumour in renal sinus
Succinate dehydrogenase–deficient renal cell carcinoma	Cannot be assessed
ALK-rearranged renal cell carcinomas	Not identified
 SMARCB1-deficient renal medullary carcinoma Other, b specify 	Present in fat and/or vascular spaces in the renal sinus
Other, specify	Tumour extends beyond Gerota's fascia
	Cannot be assessed
	Not identified
	Present
Comments	Tumour in major veins (renal vein or its segmental branches)
	Cannot be assessed
	Not identified
	Present
^a Occasionally more than one histologic type of carcinoma occurs within	Tumour in inferior vena cava
the same kidney specimen. Each tumour type should be separately recorded.	Cannot be assessed
b This would apply to cases that are pending additional studies to identify	Not identified
molecularly defined subtypes.	O Present
HISTOLOGICAL TUMOUD CDADE (WILLO (ICUD)	Tumour in renal vein wall
HISTOLOGICAL TUMOUR GRADE (WHO/ISUP)	Not identified Present
○ Not applicable ^c	Tumour in pelvicalyceal system
Cannot be assessed	Cannot be assessed
 Grade 1 - Nucleoli absent or inconspicuous and basophilic at 400x magnification 	Not identified
Grade 2 - Nucleoli conspicuous and eosinophilic at	Present
400x magnification, visible but not prominent at 100x	Tumour in adrenal gland
magnification	Cannot be assessed
 Grade 3 - Nucleoli conspicuous and eosinophilic at 100x magnification 	Not identified
Grade 4 - Extreme nuclear pleomorphism and/or multi	Present
nuclear giant cells and/or rhabdoid and/or sarcomatoid	Direct extension
differentiation	Metastasis
^c For further information see Note – HISTOLOGICAL TUMOUR GRADE	Tumour in other organs/structures
(WHO/ISUP).	Not identified
SARCOMATOID FEATURES	Present, <i>specify site(s)</i>
○ Not identified	V
Present	
1	
Extent of sarcomatoid	LYMPHOVASCULAR INVASION IN ADJACENT KIDNEY
component %	Not identified
	Present
RHABDOID FEATURES	
Not identified	MARGIN STATUS
Present	Cannot be assessed
	O Not involved
NECROSIS ^d	Involved (select all that apply)
○ Indeterminate	Renal parenchymal margin (partial nephrectomy only)
Not identified	Renal capsular margin (partial nephrectomy only)
Present	Perinephric fat margin (partial nephrectomy only)
1	Gerota's fascial margin
Extent of necrosis	☐ Renal vein margin☐ Ureteral margin
(Applicable to clear cell renal cell %	Other, specify
carcinoma only)	
^d Core element for clear cell renal cell carcinoma and chromophobe renal cell carcinoma only; in all other cases it is non-core.	

LYMPH NODE STATUS	Representative blocks for ancillary studies, specify
No nodes submitted or found	those blocks best representing tumour and/or normal tissue for further study
Number of lymph nodes examined	Tot Tartifet Study
Not involved	
Number of positive lymph nodes	
Number cannot be determined	
Size of largest focus	
Extranodal extension Not identified Present	
^e Extranodal extension is synonymous with extracapsular extension/ spread.	
COEXISTING PATHOLOGY IN NON-NEOPLASTIC KIDNEY	PATHOLOGICAL STAGING (UICC TNM 8 th edition) ^f
(select all that apply)	TNM Descriptors (only if applicable) (select all that apply)
Not identified	$\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $
Insufficient tissue for evaluation (<5 mm tissue adjacent to the tumour)Tubular (papillary) adenoma(s)	 r - recurrent tumours after a disease free period y - classification is performed during or following multimodality treatment
Glomerular disease, <i>specify type</i>	Primary tumour (pT)
	 TX⁹ Primary tumour cannot be assessed
Tubulointerstitial disease, specify type	○ T0 No evidence of primary tumour
	 T1 Tumour 7 cm or less in greatest dimension, limited to kidney
Vascular disease, <i>specify type</i>	T1a Tumour 4 cm or less
vasculai disease, specily type	T1b Tumour more than 4 cm but not more than 7 cm
	T2 Tumour more than 7 cm in greatest dimension, limited to kidney
Cyst(s), specify type	T2a Tumour more than 7 cm but not more than 10 cm
	T2b Tumour more than 10 cm, limited to the kidneyT3 Tumour extends into major veins or perinephric
Other, specify	tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia
	T3a Tumour extends into the renal vein or its segmental branches, or invades pelvicalyceal system, or tumour invades perirenal and/or renal sinus (peripelvic) fat but not beyond Gerota's fascia
	 T3b Tumour extends into the vena cava below the diaphragm
ANCILLARY STUDIES	 T3c Tumour extends into the vena cava above the diaphragm or invades the wall of the vena cava
Not performed Performed (select all that apply)	 T4 Tumour invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)
Immunohistochemistry, specify test(s) and result(s)	<i>5</i> ,
	Regional lymph nodes (pN)
	NX ⁹ Regional lymph nodes cannot be assessed
	N0 No regional lymph node metastasisN1 Metastasis in regional lymph node(s)
Molecular findings, specify test(s) and result(s)	MI Metastasis in regional lymph hode(s)
	Distant metastasis (pM)
	Not applicable
	M1 Distant metastasis
Other, record test(s), methodology and result(s)	f Reproduced with permission. Source: UICC TNM Classification of Malignant Tumours, 8th Edition, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley (incorporating any errata published up until 12th July 2024).
	⁹ TX and NX should be used only if absolutely necessary.